It was another busy week! Bayer reduced its executive suite from 14 to 8 as part of a major restructuring.

Meanwhile, the government announced it will pay for Wegovy for patients with heart disease after the Novo Nordisk therapy was approved earlier this month for the cardiovascular indication.

Plus, Mirador’s emergence from stealth and the FDA’s approval of the third therapy for Duchenne muscular dystrophy in less than a year.